Navigation Links
HRT Can Lead to Abnormal Mammograms, Biopsies

That may limit effectiveness of these breast cancer detection methods, study says

MONDAY, Feb. 25 (HealthDay News) -- Women who take combined hormone therapy for about five years have a higher risk of abnormal mammograms and breast biopsies.

This, in turn, may decrease the effectiveness of these methods of detecting breast cancer, according to a new study published in the Feb. 25 issue of Archives of Internal Medicine.

"Women need to be aware of the risks, and it's not just risk of increased breast cancer. It's a risk of possibly having abnormal mammograms and really being tortured by them," said Dr. Kristin Byrne, chief of breast imaging at Lenox Hill Hospital in New York City, who was not involved with the study. "It's a whole slew of things they need to be aware of before making a decision to go on hormone therapy."

Study lead author Dr. Rowan Chlebowski, a medical oncologist with the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, said that for women with severe menopausal symptoms, the new findings "won't be an issue."

"It [hormone-replacement therapy] is safer than we thought maybe a year and a half ago," he said. "Certainly, no one is going to brush off a breast biopsy. But for women trying to decide whether to start on hormone therapy or who want to see if their symptoms get better, they have to think about whether they would mind having a call back" for a mammogram.

The landmark Women's Health Initiative (WHI) study found that combined estrogen plus progestin hormone replacement therapy (HRT) increased the risk of breast cancer. One recent study indicated that the risk was greater for lobular breast cancer than ductal carcinoma malignancy.

Since 2003, there has been a decline in breast cancer incidence that coincided with a decline in HRT use for menopausal symptoms. Nevertheless, Chlebowski pointed out, "a lot of people are still using hormone therapy."

For the new study, the authors looked at 16,608 women who participated in the WHI from 1993 to 1998. The women were randomly assigned to receive combined hormone replacement therapy (estrogen plus progesterone) or a placebo.

Mammograms and breast exams were conducted annually and biopsies performed, if indicated.

More than one in 10 women had otherwise avoidable mammogram abnormalities (an increase of 11 percent), while one out of 25 women had otherwise avoidable breast biopsies (an increase of 4 percent), after taking the hormone therapy for five years.

Ten percent of women in the HRT group had to have a biopsy, compared to 6.1 percent in the placebo group. Yet the biopsies only detected 14.8 percent of cancers in the HRT group, compared with 19.6 percent in the placebo group.

"Your breasts become denser [with HRT], and we all know that mammography isn't as sensitive for the detection of breast cancer in women with dense breasts," Byrne explained.

The increase in abnormal mammograms persisted for at least 12 months even after discontinuing hormone therapy, the study found.

For the medical community, Chlebowski said, this finding "focuses attention that diagnosis is hindered. We have additional imaging modalities, and maybe we should evaluate them to see if we can get rid of this hindrance or delay in diagnosis. It hasn't been a factor for attention before, but it probably should be."

Chlebowski has consulted for several pharmaceutical companies.

A prepared statement from Wyeth Pharmaceuticals, which makes the hormonal product Prempro, said: "While the [study] authors report a link between an increase in abnormal mammograms and breast density among women taking combined estrogen plus progestin, this does not mean they are at an increased risk for breast cancer.

"The data used in this sub-analysis were taken from the combined estrogen plus progestin database of the WHI study and does not reflect the experience of the majority of women taking hormone therapy -- those who take estrogen-alone," the statement concluded.

More information

For more on the Women's Health Initiative, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Rowan T. Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Kristin Byrne, M.D., chief of breast imaging, Lenox Hill Hospital, New York City; Wyeth statement; Feb. 25, 2008, Archives of Internal Medicine

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Siblings of schizophrenia patients display subtle shape abnormalities in brain
2. Chromosome Abnormalities Raise Risk for Autism
3. Body Abnormalities, Childhood Cancer May Share Genes
4. Scientists identify brain abnormalities underlying key element of borderline personality disorder
5. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
6. Abnormal glutamine repeats interfere with key transcription factor, leading to neurodegeneration
7. Abnormal immune cells may cause unprovoked anaphylaxis
8. Grant Supports Study of Abnormal Ring-Shaped Chromosomes
9. Clinical depression linked to abnormal emotional brain circuits
10. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
11. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
Post Your Comments:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... ... exchange technology and teleradiology services, has added Chris Hafey and Claude Hooton to ... at the Radiological Society of North America (RSNA) 2015 Annual Meeting and continues ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology: